UK clinical-stage biotech Elevara Medicines today announced the close of a $70 million Series A financing. The round was ...

US pharma giant Merck & Co has announced the start of construction for a $3 billion, 400,000-square-foot pharmaceutical ...

Just days after gaining similar regulatory approval in the USA, AstraZeneca and Amgen’s Tezspire (tezepelumab) has been ...

French drugmaker Ipsen today announced a definitive agreement to acquire all issued and outstanding shares of ImCheck ...

The Russian government plans to double the volume of localized active pharmaceutical ingredients (APIs) within the next five ...

Russian drugmaker Pharmasyntez and China's Hualan Bio will join forces on the development of new drugs and technology ...

French biopharma Ipsen (Euronext: IPN) has reported a strong third quarter, with total revenue rising 9% to 915 million euros ...

In Europe, the European Medicines Agency (EMA) was active this week with its Committee for Medicinal Products for Human Use ...

Positive results from the global ElevAATe Phase II study have shown that efdoralprin alfa met all primary and key secondary endpoints when dosed every three weeks (Q3W) or four weeks (Q4W) in adults ...

Aspire Pharma, a rapidly growing UK-based specialty generics business, has announced the acquisition of Charlwood Pharma, a ...

Boston, USA-based neuroscience company Newleos Therapeutics has appointed Timothy Noyes as president and chief executive (CEO).

Oncolytic immunotherapies specialist Replimune Group has announced that the US Food and Drug Administration (FDA) has ...